BULLISHWHALES
BullishWhales · Analysts · Analyst Profile
BW Score Rank#70 of 347

Serge Belanger

Needham · Equity Research Analyst
EstablishedRating since 2022No new ratings since Jun 2025

Analyst rating accuracy & track record

Serge Belanger is an equity research analyst at Needham. Bullish Whales has scored 73 of their stock calls across 13 companies. Their picks beat their sector 49% of the time over the next 12 months, and their price targets were reached 40% of the time within a year.

Win % vs sector
49%
PT Hit % (12mo)
40%
Avg sector-excess
+0.9%
Scored calls
73
Tickers
13
Tier
Established

Track record

Bullish Whales has scored 73 of Serge Belanger's stock calls across 13 companies, dating back to 2022. Their rated stocks beat their own sector 49% of the time over the next 12 months. On a typical call, a Belanger pick returned +0.9% more than its sector over the following year.

Of the scored calls, 73 were bullish (Buy). Most of their coverage sits in Healthcare. Every number on this page is an estimate from our own data. It is for education only and is not investment advice.

Coverage & ratings

Ratings & price targets

StockRatingPrice targetRated12-mo vs sectorPT hit
LQDALiquidia Technologies Inc
Buy$32.00Jun 2025+221.4%Hit
LQDALiquidia Technologies Inc
Buy$25.00May 2025+297.5%Hit
ARQTArcutis Biotherapeutics Inc
Buy$20.00May 2025+34.9%Hit
LQDALiquidia Technologies Inc
Buy$25.00May 2025+282.8%Hit
TRVITrevi Therapeutics Inc
Buy$24.00May 2025+110.8%Miss
LQDALiquidia Technologies Inc
Buy$25.00May 2025+241.4%Hit
PCRXPacira BioSciences, Inc.
Buy$30.00May 2025−16.5%Miss
EOLSEvolus Inc
Buy$22.00May 2025−45.2%Miss
ESPREsperion Therapeutics Inc
Buy$4.00May 2025+241.9%Hit
CRMDCorMedix Inc
Buy$15.00May 2025−44.0%Hit
OCULOcular Therapeutix Inc
Buy$14.00May 2025+28.4%Hit
BCRXBioCryst Pharmaceuticals Inc
Buy$17.00May 2025−21.7%Miss
ESPREsperion Therapeutics Inc
Buy$5.00Apr 2025+105.2%Miss
HRTXHeron Therapeuti
Buy$4.00Apr 2025−61.7%Miss
BCRXBioCryst Pharmaceuticals Inc
Buy$15.00Apr 2025+30.6%Miss
LQDALiquidia Technologies Inc
Buy$25.00Apr 2025+176.6%Hit
EOLSEvolus Inc
Buy$22.00Apr 2025−67.6%Miss
CRMDCorMedix Inc
Buy$12.00Apr 2025−5.1%Hit
COLLCollegium Pharmaceutical Inc
Buy$46.00Apr 2025+30.2%Hit
ARQTArcutis Biotherapeutics Inc
Buy$20.00Apr 2025+70.1%Hit
ESPREsperion Therapeutics Inc
Buy$5.00Apr 2025+112.1%Miss
KALVKalvista Pharmaceuticals Inc
Buy$28.00Apr 2025+68.3%Miss
PCRXPacira BioSciences, Inc.
Buy$32.00Apr 2025−19.8%Miss
OCULOcular Therapeutix Inc
Buy$15.00Apr 2025+13.3%Hit
TRVITrevi Therapeutics Inc
Buy$24.00Apr 2025+132.3%Miss
ARQTArcutis Biotherapeutics Inc
Buy$20.00Apr 2025+50.5%Hit
CRMDCorMedix Inc
Buy$12.00Mar 2025−2.5%Hit
KALVKalvista Pharmaceuticals Inc
Buy$28.00Mar 2025+51.2%Miss
LQDALiquidia Technologies Inc
Buy$25.00Mar 2025+139.9%Hit
TRVITrevi Therapeutics Inc
Buy$24.00Mar 2025+60.4%Miss
KALVKalvista Pharmaceuticals Inc
Buy$28.00Mar 2025+29.3%Miss
OCULOcular Therapeutix Inc
Buy$15.00Mar 2025+5.1%Hit
EOLSEvolus Inc
Buy$22.00Mar 2025−63.0%Miss
HRTXHeron Therapeuti
Buy$4.00Feb 2025−54.3%Miss
PCRXPacira BioSciences, Inc.
Buy$32.00Feb 2025−15.2%Miss
ARQTArcutis Biotherapeutics Inc
Buy$20.00Feb 2025+114.4%Hit
EOLSEvolus Inc
Buy$22.00Jan 2025−78.6%Miss
PCRXPacira BioSciences, Inc.
Buy$30.00Jan 2025−8.8%Miss
COLLCollegium Pharmaceutical Inc
Buy$46.00Jan 2025+29.3%Hit
LQDALiquidia Technologies Inc
Buy$19.00Jan 2025+179.5%Hit
PCRXPacira BioSciences, Inc.
Buy$30.00Dec 2024+24.4%Miss
ARQTArcutis Biotherapeutics Inc
Buy$20.00Dec 2024+97.5%Hit
ESPREsperion Therapeutics Inc
Buy$6.00Dec 2024+48.2%Miss
KALVKalvista Pharmaceuticals Inc
Buy$28.00Dec 2024+59.4%Miss
HRTXHeron Therapeuti
Buy$4.00Dec 2024−31.8%Miss
LQDALiquidia Technologies Inc
Buy$19.00Nov 2024+176.0%Hit
HRTXHeron Therapeuti
Buy$4.00Nov 2024−18.1%Miss
PCRXPacira BioSciences, Inc.
Buy$22.00Nov 2024+31.4%Hit
ARQTArcutis Biotherapeutics Inc
Buy$18.00Nov 2024+124.9%Hit
HRTXHeron Therapeuti
Buy$5.00Sep 2024−29.7%Miss
Go to

Serge Belanger: analyst track record FAQ

Is Serge Belanger a good stock analyst?

Yes, by track record. Serge Belanger ranks number 70 of 347 of the analysts Bullish Whales scores, with a BW Score of 53 out of 100. Past results do not guarantee future ones.

What is Serge Belanger's win rate?

Serge Belanger's win rate is 49%. Across 73 scored calls, their rated stocks beat their sector 49% of the time over the next 12 months. On a typical call they returned +0.9% more than the sector.

What stocks and sectors does Serge Belanger cover?

Serge Belanger covers 13 companies, with the most coverage in Healthcare. See the ratings table above for every scored call and its outcome.

Are Serge Belanger's price targets accurate?

Serge Belanger's price targets are reached within 12 months 40% of the time. The base rate across all analysts Bullish Whales tracks is about 43 percent.

How accurate are Wall Street analyst price targets?

Most analyst price targets are not reached on schedule. Across every target Bullish Whales scores, the stock reaches the target within 12 months only about 43 percent of the time, which is why it helps to compare hit rates analyst by analyst.

Should I follow Serge Belanger's stock ratings?

Their track record is strong, but no analyst is right every time. Follow the long-term track record rather than any single rating, size your positions to your own risk, and treat this as research, not investment advice.

How does Bullish Whales score analyst accuracy?

Bullish Whales scores every rating on real prices. We enter at the closing price on or after the call date, with no look-ahead, then measure the 12-month return above the stock's sector ETF and check whether the price target was reached. Scores are pulled toward the population average and corrected for testing thousands of analysts at once, so they reflect repeatable skill rather than luck.

How does Serge Belanger rank among Wall Street analysts?

Serge Belanger ranks number 70 of 347 by BW Score. We rank analysts by their realized 12-month sector-excess return and require a minimum number of calls so a few lucky picks cannot reach the top.

Browse the full analyst leaderboardHow analyst accuracy is scored

Every score, Win %, PT Hit % and rank is an estimate Bullish Whales calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.

v1.0.30